EFFECTS OF HYPERBARIC OXYGEN THERAPY (HBOT) ON SARS-COV-2+ HOSPITALIZED PATIENTS WITH HYPOXEMIC RESPIRATORY FAILURE

KELLER G.A.; EIZAGUIRRE L; CORIA J; DI GIROLAMO G; MIRANDA S

Congreso; Reunión Anual de Sociedades de BioCiencias. LXVII Reunión Anual de la Sociedad Argentina de Investigaciones Clínicas (SAIC), LXX Reunión Anual de la Sociedad Argentina de Inmunología (SAI) & 3rd French-Argentine Immunology Congress (FAIC).; 2022

SAIC-SAI

HBOT has been proposed to address COVID-19-associated hypoxia. However, its actions at the molecular level are poorly known. Method: 50 patients with hypoxemic COVID-19 pneumonia from Hospital Santojanni were recruited between May-August 2021 in a randomized controlled study comparing standard care (C group) versus standard care plus HBOT (H group) in 1:1 proportion. HBOT was performed with Biobarica® chambers at 1.45 atm, 90 min/day for 5 days. Oxygen saturation (SatO2) was followed up. Blood was obtained at t=0 and t=5d. White blood cell (WC) count, lymphocytes (L) and platelets (P) and serum analysis (glucose, urea, creatinine, sodium, potassium, ferritin, D dimer, LDH and CRP) were carried out. Plasma levels of sVCAM, sICAM, sPselectin, SAA and MPO, and of a cytokine panel (IL-1β, IL-1RA, IL-6, TNFα, IFNα, IFNγ, IL-15, VEGF, MIP1α, IL-12p70, IL-2 and IP-10) were measured by multiplex magnetic bead assays (Merck Millipore). Angiotensin Converting Enzyme 2 (ACE-2) levels were determined employing a comercial kit (R&D Systems)Results: The average basal SatO2 was 85±3%. The days needed to reach SatO2>90% were: H: 3±1 and C: 5±1 (P